NEW YORK (GenomeWeb) – Meridian Bioscience today reported a 1 percent decline in revenues for its fiscal third quarter. 

For the three months ended June 30, Meridian posted $50.1 million in revenues, down from $50.7 million in the year-ago period but above the consensus Wall Street estimate of $49.2 million. 

The company's life science segment saw revenues grow 8 percent to $14.2 million from $13.1 million, while the diagnostics segment saw a 4 percent decline in revenues to $35.9 million from $37.5 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.